News AtriCure, Inc.

Equities

ATRC

US04963C2098

Delayed Nasdaq Other stock markets 03:50:00 2024-04-25 pm EDT			5-day change	1st Jan Change
22.56 ^USD	-2.13%		-3.48%	-36.75%

Apr. 23	Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	MT
Apr. 18	AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Upgrades AtriCure to Outperform, Price Target at $32	Apr. 23	MT
AtriCure Announces Launch of the cryoSPHERE+ Probe for Post-Operative Pain Management	Apr. 19	AQ
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative Pain Management	Apr. 18	BU
AtriCure, Inc. Announces Launch of the CryoSPHERE®?+ Probe for Post-Operative Pain Management	Apr. 18	CI
AtriCure to Announce First Quarter 2024 Financial Results	Apr. 10	BU
AtriCure to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Mar. 26	BU
AtriCure Insider Sold Shares Worth $307,510, According to a Recent SEC Filing	Mar. 07	MT
Atricure, Inc. Appoints Shlomi Nachman as Director, Member of Each of the Board?s Strategy Committee and Compliance, Quality and Risk Committee	Feb. 27	CI
UBS Adjusts AtriCure Price Target to $58 From $57, Maintains Buy Rating	Feb. 16	MT
Stifel Adjusts Price Target on AtriCure to $42 From $50, Maintains Buy Rating	Feb. 16	MT
Needham Adjusts Price Target on AtriCure to $46 From $44, Keeps Buy Rating	Feb. 16	MT
AtriCure Q4 Loss Widens, Revenue Rises; 2024 Guidance Set	Feb. 15	MT
Transcript : AtriCure, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (ATRC) ATRICURE Reports Q4 Revenue $106.5M, vs. Street Est of $104.2M	Feb. 15	MT
AtriCure: Q4 Earnings Snapshot	Feb. 15	AQ
AtriCure Reports Fourth Quarter 2023 and Full Year 2023 Financial Results	Feb. 15	BU
Atricure, Inc. Provides Earnings Guidance for 2024	Feb. 15	CI
AtriCure, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
AtriCure to Announce Fourth Quarter and Full Year 2023 Financial Results and Participate in 2024 BTIG Medical Technology Conference	Jan. 25	BU
UBS Adjusts AtriCure Price Target to $57 From $56, Maintains Buy Rating	Jan. 22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News AtriCure, Inc.

Equities

ATRC

US04963C2098

Summary

Filters